Cavernous hemangiomas that manifest as a pr imary tumor ofthe infrat emporal f ossa are exceedingly rare. We report such a case in a 40-year-old woman. Her lesion was excised via a transantral anterior approach. Although this approa ch is usually recommended only f or biopsy, in selected cases it can be used to excise a lesion without causing any significant complications. We recommend the transantral anterior approa chfor relativ ely small, benign lesions that show no evidence of invasion into surrounding tissues because it does not expose the pati ent to surgical complications such as transient or permanent fa cial nerve injury or cosmetic def ormity.
Introduction
Hemangioma s are the most common benign tumors in infants; in fact, they are the most common of all birth defect s. They are benign vascular malformations that originate in mesodermal nests of vasoform ative tissue. Synonyms for hemangiom a are benign mesenchymoma , infiltratin g angiolipoma, angiofibrolipoma, hemartoma , and cavernous hemangioma.l? Depending on their histology, hemangiomas are classified as capillary (sm allvessel), cavernous (large-ve ssel), and mixed-type. I In adults, the most common type is the cavernou s hemangioma. There have been several reports of cavernous hemangiomas of the oral cavity, pharynx, and larynx .l" but these neopla sms are exceedingly rare as prima ry tumors of the infratemporal fossa.v' " This article describes our diagnosis and treatment of a cavernous hemangioma that was located in infratemporal fossa.
Case report
A 40-year-old woman was admitted to the Department of Otolar yngology-Head and Neck Surgery at Hacettepe University in Ankara, Turkey, with a history of right facial pain and headache of2 years ' duration. Five months earlier, a neuro surgeon had diagno sed trigeminal neuralgia and had prescribed carbamazepine. Two months prior to her admission to our ENT depa rtment, she had noticed that a mass on her right cheek became visible whenever she opened her mouth.
The result s of her physical examination, routine laboratory tests, che st x-ray, and panoramic x-ray of the mandible were all norm al. Magnetic resonance imaging revealed the pre sence of a well-circumscribed, cylindrical mass in the right infratemporal fossa whose dimension s were estimated to be 2 x 1.5 x 3 em (figure 1). Her angiogram revealed a faint tumor blush without a significant feeder vessel.
A transantral anterior surgical approach with a Caldwell-Luc incision was used to gain acce ss to the infratemporal fossa. The right maxill ary sinus was norm al. The posterior wall of the maxillary sinus was fene strated with a hammer and chisel until the mass could be seen. Exposure was improved by removin g the posterior and lateral walls of the maxilla ry sinu s with a rongeu r. The mass was easily detached and removed from the surrounding tissues by blunt dissection. The re was no hemorrhage.
On visual inspection, the mass was brown and had regular contou rs, and its actual measurement was 3 x 2.5 x I ern. Microscopic examin ation with hematoxylin and eosin staining revealed that the lesion contained large vessels with cy stically dilated lumin a, which were filled with erythrocyte s and fibrou s tissue interspersed between these vessels (figure 2). These features are chara cter istic of a cavernou s hemangi oma.
The patient experienced no postoperative complications, and she was discharged 2 day s following surgery. Followup computed tomography obtained I year after surgery revealed no evidence of recurrence ( figure 3 ).
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Figur e 1. Ma gnetic reso nance imaging shows a mass in the right infratemp oral fossa , estima ted to measure 2 x 1.5 x 3 em.
Discussion
Hemangiom as are cong enital , benign , well-circumscribed malformations of the vascul ature . Capillary hemangiomas are more common in infant s, while cavernous lesions are more common in adults. Capillary hemangiomas tend to be more superficial than cavernous lesions , as they usually occur in the dermal layer, and they gradually undergo involution. Cavernous hemangiomas appear as globul ar, compressible, bright-red or deep-purple lesions , which sometimes temporarily enlarge during straining. They tend to involv e the deep , subcutaneous tissues. Cavernous hemangiomas are less likely to spontaneously invo lute ."
Nearly all tumors seen in the infra temporal fossa are either metastatic or exten sions of intram uscular or osseous Iesions."-" Primary tumors of the infratemporal fossa are rare, and primary hemangiomas of the infratemporal fossa are exceedingly rare, as only a few cases have been reported in the literature.v'?
The treatment option s include surgery, irradi ation , laser therapy, cryotherapy, and instillation of sclerosing agents.I I The most effective treatment is a wide surgical excision. Surgery is indicated for large tumors that invade adjacent structures and cause functional derangement, disfigurement, or pain. Postoperative radiation therapy is suggested for troublesome recurrent tumors, but its use as a primary treatment is not recornmended. v" :"
The complete removal of an infratemporal fossa lesion can be difficult becau se of the anatomic complexity and the inaccessibility of some masses. Additionally, complete exc ision raises concerns with regard to major postoperative complication s. Both lateral and anterior approaches have been used to gain access to the infratemporal fos sa. The lateral approaches include the direct, the tran sparotid, and the tran sotic procedures.v'"The major complications of these operations are facial pa lsy , trismus, enophthalmus, malunion, and hearing loss.' The most common anterior approaches are the transmandibular, the transoral , and the transmaxillary procedures, all of which require an osteotomy. Complication s of these procedures include malunion, postoperative infection , neural deficit s, dysphagia, and facial scarring." :" In addition , Korn fehl et al have described a relatively new transpal atine approach that does not require an osteotomy."
The transantral anterior approach that we describe involved a Caldwell-Luc procedure and the removal of the posterior wall of the maxillary sinu s to gain acce ss to the infratemporal fossa . Thi s technique is usually recommended only for biopsy , but in selected cases it can be
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